Cargando…

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5261548/ https://www.ncbi.nlm.nih.gov/pubmed/28174493 http://dx.doi.org/10.2147/CEOR.S118835

Ejemplares similares

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
por: Ponzetti, Clemente, et al.
Publicado: (2016)

Continuous Intravenous versus Subcutaneous Administration of Insulin for Glycemic Variability in Acute Ischemic Stroke [Corrigendum]
Publicado: (2022)

Validation of a treatment satisfaction questionnaire in non-Hodgkin lymphoma: assessing the change from intravenous to subcutaneous administration of rituximab
por: Theodore-Oklota, Christina, et al.
Publicado: (2016)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)

Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2017)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013)

Corrigendum to “Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib”
por: Gorini, Stefania, et al.
Publicado: (2019)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016)

Tumor necrosis factor-308 polymorphism with the risk and prognosis of non-Hodgkin lymphomas: a meta-analysis study [Corrigendum]
Publicado: (2016)

Corrigendum to “Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer”
por: Yang, Guangda, et al.
Publicado: (2020)

Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study
por: Abad-Sazatornil, María Reyes, et al.
Publicado: (2021)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Corrigendum to “Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis”
Publicado: (2021)

Drug prescription appropriateness in the elderly: an Italian study [Corrigendum]
Publicado: (2017)

Targeted Delivery of Doxorubicin Utilizing Chitosan Nanoparticles Surface Functionalized with Anti Her2 Trastuzumab [Corrigendum]
Publicado: (2022)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
Publicado: (2013)

One health surveillance strategy for coronaviruses in Italian wildlife – CORRIGENDUM
por: Leopardi, Stefania, et al.
Publicado: (2023)

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)

Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
por: Cherin, Patrick, et al.
Publicado: (2015)

Corrigendum to “Radiological Features of Gastrointestinal Lymphoma”
por: Lo Re, Giuseppe, et al.
Publicado: (2016)

Hospital Cost Savings for Sequential COPD Patients Receiving Domiciliary Nasal High Flow Therapy [Corrigendum]
Publicado: (2022)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives
por: Papadmitriou, K., et al.
Publicado: (2015)

Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study
por: García‐Muñoz, Ricardo, et al.
Publicado: (2019)

Corrigendum to: Rice Galaxy: an open resource for plant science
por: Juanillas, Venice, et al.
Publicado: (2019)

Argon plasma improves the tissue integration and angiogenesis of subcutaneous implants by modifying surface chemistry and topography [Corrigendum]
Publicado: (2019)

The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home
por: Tjalma, WAA, et al.
Publicado: (2017)

Long-term intravenous administration of carboxylated single-walled carbon nanotubes induces persistent accumulation in the lungs and pulmonary fibrosis via the nuclear factor-kappa B pathway [Corrigendum]
Publicado: (2017)

Repeated Intravenous Administration of Silica Nanoparticles Induces Pulmonary Inflammation and Collagen Accumulation via JAK2/STAT3 and TGF-β/Smad3 Pathways in vivo [Corrigendum]
Publicado: (2023)

CORRIGENDUM to “Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma”
Publicado: (2020)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Corrigendum to “Genotype-Phenotype Characterization of Novel Variants in Six Italian Patients with Familial Exudative Vitreoretinopathy”
por: Iarossi, Giancarlo, et al.
Publicado: (2017)

Minimization of administration route errors with subcutaneous rituximab
por: Liptrott, Sarah, et al.
Publicado: (2016)

Clinical experimentation with aerosol antibiotics: current and future methods of administration [Corrigendum]
Publicado: (2014)

Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting [Corrigendum]
Publicado: (2021)

Corrigendum to “A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial” [Int. Immunopharmacol. 96 (2021) 107743]
por: Sharma, Alok, et al.
Publicado: (2022)

Corrigendum to “Designing and evaluating an automated intravenous dosage medication calculation tool for reducing the time of stat medication administration in a pediatric emergency department” [Heliyon 6 (6) (June 2020) Article e04140]
por: AlGoraini, Yara, et al.
Publicado: (2020)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Corrigendum: Towards national health insurance: Alignment of strategic human resources in South Africa
por: Mofolo, Nathaniel, et al.
Publicado: (2021)

Corrigendum to “T Helper 17/Regulatory T Cell Balance and Experimental Models of Peritoneal Dialysis-Induced Damage”
por: Liappas, Georgios, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2rmovbqmeaealisu0lqmr7j0pi